ProRelix Research is pleased to announce its participation in CPHI & PMEC China 2025, scheduled from 24–26 June at the Shanghai New International Expo Centre (SNIEC). Recognized as one of the most influential events in the global pharmaceutical and healthcare industry, the exhibition will bring together key stakeholders, innovators, and decision-makers from across the world.
At this prestigious event, ProRelix Research will be showcasing its global capabilities in clinical research, data management, medical writing, pharmacovigilance, regulatory affairs, and ICH GCP compliance. With a proven track record in delivering high-quality, compliant, and result-driven solutions, our team is dedicated to supporting sponsors and partners in achieving their research objectives efficiently and effectively.
Our participation at CPHI & PMEC China reflects our commitment to innovation, collaboration, and excellence in healthcare research. We look forward to engaging in meaningful discussions with industry professionals, exploring new partnerships, and exchanging insights on the evolving regulatory and scientific landscape.
Visitors to the event will have the opportunity to meet our experts and learn how ProRelix Research can serve as a strategic partner in navigating the complexities of global clinical trials while maintaining the highest standards of quality, ethics, and compliance.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.